

Attorney Docket No.: RTS-0345
Inventors: Borchers and Dobie
Serial No.: 10/007,010
Filing Date: December 4, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): An oligonucleotide 8 to 80 nucleobases in length targeted to nucleobases 67 through 144 of a 5'-untranslated region, nucleobases 258 through 1684 of a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule of SEQ ID NO: 3 encoding hematopoietic cell protein tyrosine kinase, wherein said ~~compound~~ oligonucleotide specifically hybridizes with one of said regions and inhibits the expression of hematopoietic cell protein tyrosine kinase.

Claim 2 (previously amended): The oligonucleotide of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (previously amended): The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (previously amended): The oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Attorney Docket No.: RTS-0345
Inventors: Borchers and Dobie
Serial No.: 10/007,010
Filing Date: December 4, 2001
Page 3

Claim 6 (previously amended): The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (previously amended): The oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (previously amended): The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (previously amended): The oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (previously amended): The oligonucleotide of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (previously amended): A composition comprising the oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Attorney Docket No.: RTS-0345
Inventors: Borchers and Dobie
Serial No.: 10/007,010
Filing Date: December 4, 2001
Page 4

Claim 14 (currently amended): The composition of claim 12 wherein the ~~compound~~ oligonucleotide is an antisense oligonucleotide.

Claim 15 (currently amended): A method of inhibiting the expression of hematopoietic cell protein tyrosine kinase in cells or tissues comprising contacting said cells or tissues *in vitro* with the ~~compound~~ oligonucleotide of claim 1 so that expression of hematopoietic cell protein tyrosine kinase is inhibited.

Claims 16-20 (canceled).